Enanta Pharmaceuticals (ENTA) Other financing activities (2012 - 2025)

Enanta Pharmaceuticals (ENTA) has 15 years of Other financing activities data on file, last reported at $69.8 million in Q1 2026.

• Quarterly Other financing activities rose 74362.77% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.9 million (up 137252.94% YoY) and the FY2023 annual result came in at $200.0 million, changed N/A from the prior year.
• Other financing activities improved to $69.8 million in Q1 2026, from $141000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $198.0 million in Q2 2023 to a low of -$18.3 million in Q3 2022.
• A 5-year average of $17.3 million and a median of $94000.0 in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities plunged 2043.9% — and 2026, when it soared 74362.77%.
• Tracing ENTA's Other financing activities over 5 years: stood at $1.1 million in 2022, then jumped by 17483.66% to $198.0 million in 2023, then plunged by 99.95% to $94000.0 in 2024, then jumped by 50.0% to $141000.0 in 2025, then jumped by 49408.51% to $69.8 million in 2026.
• The last three Other financing activities figures came in at $69.8 million (Q1 2026), $141000.0 (Q4 2025), and -$94000.0 (Q3 2025), per Business Quant data.